The aim of the study is to determine the efficacy and safety of treatment with the drug eplerenone in patients with chronic central serous chorioretinopathy.

Inclusion Criteria:

• Chronic central serous chorioretinopathy (CSCR) with persistent subretinal fluid on OCT for more than 3 months after initial presentation .
• Written informed consent

Exclusion Criteria:

• Persons with impaired decision-making ability.
• Pregnant women or who are actively trying to conceive.
• Additional eye disease affecting the macula or posterior retina.
• Creatinine clearance < 50 ml/min
• Hyperkalemia > 5 mmol/l
• Serum creatinine > 2 mg/dl in men or > 1.8 mg/dl in women
• Treatment with potassium sparing agents or potassium
• Treatment with any other drugs known to cause interaction with eplerenone
• Microalbuminuria in patients with type 2 diabetes